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Xenograft Tumors Vascularized with Murine Blood
Vessels May Overestimate the Effect of Anti-Tumor
Drugs: A Pilot Study
Zhihong Dong1, Atsushi Imai1, Sudha Krishnamurthy1, Zhaocheng Zhang1, Benjamin D. Zeitlin1,
Jacques E. Nör1,2,3,4*
1 Angiogenesis Research Laboratory, Department of Restorative Sciences, University of Michigan School of Dentistry, Ann Arbor, Michigan, United States of America,
2 Department of Biomedical Engineering, University of Michigan College of Engineering, Ann Arbor, Michigan, United States of America, 3 Department of Otolaryngology,
University of Michigan School of Medicine, Ann Arbor, Michigan, United States of America, 4 Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan,
United States of America

Abstract
Recent evidence demonstrated that endothelial cells initiate signaling events that enhance tumor cell survival, proliferation,
invasion, and tumor recurrence. Under this new paradigm for cellular crosstalk within the tumor microenvironment, the
origin of endothelial cells and tumor cells may have a direct impact on the pathobiology of cancer. The purpose of this pilot
study was to evaluate the effect of endothelial cell species (i.e. murine or human) on xenograft tumor growth and response
to therapy. Tumor xenografts vascularized either with human or with murine microvascular endothelial cells were
engineered, side-by-side, subcutaneously in the dorsum of immunodefficient mice. When tumors reached 200 mm3, mice
were treated for 30 days with either 4 mg/kg cisplatin (i.p.) every 5 days or with 40 mg/kg sunitinib (p.o.) daily. Xenograft
human tumors vascularized with human endothelial cells grow faster than xenograft tumors vascularized with mouse
endothelial cells (P,0.05). Notably, human tumors vascularized with human endothelial cells exhibited nuclear translocation
of p65 (indicative of high NF-kB activity), and were more resistant to treatment with cisplatin or sunitinib than the
contralateral tumors vascularized with murine endothelial cells (P,0.05). Collectively, these studies suggest that the species
of endothelial cells has a direct impact on xenograft tumor growth and response to treatment with the chemotherapeutic
drug cisplatin or with the anti-angiogenic drug sunitinib.
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dedicated to the development of models of human angiogenesis
[9–12]. We have worked with a model that involves the generation
of xenograft tumors by the co-transplantation of human endothelial cells and human tumor cells seeded into biodegradable
scaffolds [13–17]. This model allows for the establishment of
human tumors vascularized with human vessels in immunodefficient mice. Using this model, we observed that endothelial cells
initiate signaling events that directly influence tumor cell survival,
proliferation, invasion and tumor recurrence [14,18–22]. During
the course of these experiments, we noticed that drugs that had a
very significant anti-tumor effect in traditional xenograft models
were not nearly as effective in the xenograft model with
humanized vasculature. We thus hypothesized that maximal
resistance to anti-tumor therapies is achieved when both
endothelial and tumor cells are human. Here, we report data that
demonstrate that xenograft tumors with humanized vasculature
grow faster than xenografts vascularized with mouse vasculature
and are more resistant to therapy with Cisplatin or Sunitinib, used
here as models of a traditional chemotherapeutic and an antiangiogenic drug.

Introduction
It is generally agreed that animal xenograft tumors constitute an
important model for studies on the pathobiology of tumors and for
the testing of new anti-tumor drugs [1–3]. The xenograft tumor
model was established in 1950s as a means to study human tumor
cells by implanting them subcutaneously in immunodeficiency
mice [4–6]. Since then, this model has been widely employed for
mechanistic studies of tumor growth and progression, and for the
screening of new anti-tumor agents. However, a retrospective
study performed by the National Cancer Institute (NCI) revealed
that the preclinical anti-tumor activity in human tumor xenografts
animal models did not correlate with Phase II therapeutic activity
in the clinical trials [7]. Considering the fact that human tumor
xenografts are still widely used, it is imperative that we understand
mechanisms involved in its shortcomings, and exploit new
approaches to improve this experimental model.
It has been proposed that subcutaneous xenograft tumor models
cannot reproduce the tumor microenvironment of human tumors
[8]. Notably, the angiogenic vasculature is a critical component of
the tumor microenvironment, and therefore much effort has been
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retrieved and processed for histology. The identity of the tumor
cell lines used here was confirmed by genotyping.

Materials and Methods
Endothelial cells
Human dermal microvascular endothelial cells (HDMEC;
Lonza, Walkersville, MD, USA) were cultured in endothelial cell
growth medium (EGM2-MV; Lonza). Mouse dermal microvascular endothelial cells (MDMEC; Celprogen, San Pedro, CA,
USA) were maintained in endothelial cell growth medium
(Celprogen). HEK293T cells were co-transfected with the
lentiviral packaging vectors psPAX2, pMD2.G, and the GFP
expression vector pGIPZ (University of Michigan Vector Core,
Ann Arbor, MI, USA) by the calcium phosphate method.
HDMEC and MDMEC were infected overnight, selected with
1 mg/ml puromycin (Invitrogen, San Diego, CA, USA) for at least
1 week, and GFP expression was detected under fluorescence
microscopy.

Ethics statement
The care and treatment of mice were in accordance with
University of Michigan’s institutional guidelines, and under a
protocol reviewed and approved by the University Committee of
Use and Care of Animals (UCUCA). UCUCA is the Ethics
committee from the University of Michigan responsible for the
regulation of animal research. All surgical procedures were
performed under anesthesia with Ketamine to minimize suffering.

Immunohistochemistry

HDMEC and MDMEC cells were cultured in endothelial
growth medium supplemented with 0–4 mM Cisplatin (Bedford
laboratories, Bedford, OH, USA) or 0–4 mM Sunitinib (LC
Laboratories, Woburn, MA, USA) for 48 hours. Cells were
harvested and incubated in 50 mg/ml propidium iodide for
30 min for analysis of apoptosis and cell cycle.

Tissue sections were deparaffinized with xylene, rehydrated
using descending concentrations of ethanol, and then exposed to
0.1% triton X-100 (Fisher, Fair Lawn, NJ, USA) for 10 minutes at
room temperature. Peroxidase activity was quenched with 1%
H2O2 in methanol for 10 minutes at room temperature and then
sections were treated with an antigen retrieval solution (Dako,
Carpinteria, CA, USA) for 20 min at 90–95uC in a water bath.
After two 10-minute washes with the Dako washing buffer (Dako),
staining was done manually by incubation of the tissue sections in
polyclonal rabbit anti-GFP (1:500, Evrogen, Moscow, Russia) or
rabbit anti-human Factor VIII antibody (1:500, NeoMarkers,
Fremont, CA, USA) overnight at 4uC followed by DAB staining
(EnVision + Dual Link System-HRP, Dako) and counterstaining
with hematoxylin. The number of microvessels in 10 random
fields/implant was counted in 8 scaffolds per experimental
condition. Alternatively, tissue sections were incubated with a
mouse monoclonal antibody against p65, conjugated to FITC
(1:500, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
overnight at 4uC. In this case, cover slips were mounted using
Vectashield with DAPI (Vector Laboratories, Burlingame, CA,
USA). Images were taken with a Nikon E800 microscope with a
camera (SPOT RT Slider; Spot Diagnostic) and processed with
the SPOT RT 3.0 software.

Sulforhodamine B (SRB) assay

Statistical analysis

HDMEC and MDMEC were plated in 96-well plates and
cultured in growth supplemented with 0–100 mM cisplatin or
sunitinib for 48 hours. Cells were fixed with a final concentration
of 10% ice-cold trichloroacetic acid solution (TCA, Sigma) at 4uC
for 1 hour, and stained with 50 ml of 0.4% sulforhodamine B
solution for 30 min at room temperature. Absorbance was
measured at 565 nm in microplate reader (GENious; TECAN,
Austria).

Data was analyzed by t-test or one-way ANOVA followed by
the Student-Newman-Keuls test with SigmaStat 2.0 software
(SPSS, Chicago, IL). Statistical significance was determined at
p,0.05.

Capillary sprouting assay
Endothelial cells (1.56105 cells/well) were cultured in 6-well
plates containing a 1.5 ml layer of gelled type I collagen (Inamed,
Santa Barbara, CA, USA), as described [17]. Cells were cultured
in endothelial growth medium supplemented with 50 ng/ml
VEGF (R & D Systems, Minneapolis, MN, USA). The number
of capillary sprouts was counted daily in 6 random microscope
fields (1006) from triplicate wells per condition. Here, and
throughout this manuscript, studies were performed in triplicate
samples/condition. At least 3 independent experiments were
performed to verify reproducibility of the data.

Flow cytometry

Results
Human and mouse endothelial cells generate similar
vascular networks in xenograft tumors

In vivo model of human tumor angiogenesis

Here, we used human dermal microvascular endothelial cells
(HDMEC) and mouse dermal microvascular endothelial cells
(MDMEC), which presented similar morphology under standard
cell culture conditions (Figure 1A and B). HDMEC and
MDMEC were stably transduced with lentivirus expressing green
fluorescence protein (GFP) to allow for their identification after
transplantation (Figure 1C and D). These cells showed similar
capacity to form capillary-like sprouts when cultured in 3-D
collagen matrices and treated with VEGF (Figure 1E and F). To
evaluate their ability to form functional vessels in vivo, we seeded
HDMEC or MDMEC stably transduced with GFP in biodegradable scaffolds and implanted them subcutaneously in immunodefficient mice. After 14 days, the scaffolds were removed and
GFP immunohistochemistry was performed to confirm that the
cells lining the blood vessels were indeed transplanted cells, and
not mouse blood vessels that invaded the scaffold (Figure 1G and
H). Microvessel density analysis showed that transplantation of

Poly-L-lactic acid (PLLA; Boehringer Ingelheim, Ingelheim,
Germany) biodegradable scaffolds measuring 66661 mm were
prepared, as described [13]. Briefly, 1.06105 tumor cells (UMSCC-17B, HN12, or HeLa) and 9.06105 GFP-tagged endothelial
cells (HDMEC or MDMEC) were seeded in each scaffold. Male
6- to 7- week-old CB-17 SCID mice (Charles River Laboratory,
Wilmington, MA, USA) were anesthetized with ketamine/
xylazine, and 2 scaffolds (one containing tumor cells and HDMEC
and the other with tumor cells and MDMEC) were implanted
bilaterally in the subcutaneous space of each mouse (8 mice in
each cohort). When the average tumor size reached around
180 mm3, mice received 4 mg/kg cisplatin (i.p.) every 5 days or
40 mg/kg sunitinib (o.r.) daily. Tumor volume was evaluated daily
by calipers by an investigator blinded for experimental groups,
until the untreated controls reached an average volume of
1,000 mm3. Immediately after euthanasia, xenografts were
PLOS ONE | www.plosone.org
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human and mouse endothelial cells gave rise to similar numbers of
microvessels (Figure 1I). Notably, blood cells were clearly visible
in GFP-positive microvessels (Figure 1G and H), which confirms
our previous observations that the engineered vasculature is
functional and capable of connecting to host vessels through
anastomosis [13].

Human and mouse endothelial cells respond differently
to a chemotherapeutic and an anti-angiogenesis drug in
vitro
To understand the impact of the species of endothelial cells on
the response to anti-cancer drugs, we performed a series of studies
using cisplatin as a model of chemotherapeutic drug and sunitinib
as a model of targeted anti-angiogenic drug. Cytotoxicity assays
showed that mouse endothelial cells are more sensitive to cisplatin
than human endothelial cells (Figure 3A). In contrast, sunitinib
was equally toxic to both mouse and human endothelial cells. As
expected, cisplatin induced G2 cell cycle arrest and apoptosis in
both human and murine endothelial cells (Figure 3C and E).
However, the mouse endothelial cells were significantly more
sensitive to induction of apoptosis by cisplatin than the mouse
endothelial cells (Figure 3C). For sunitinib, we observed more
apoptosis in the mouse endothelial cells than the human
endothelial cells (Figure 3D). However, this effect was likely
offset by the observation that the proportion of proliferating
endothelial cells (i.e. cells in the ‘‘S’’ phase of cell cycle) was
consistently higher than in the MDMEC group than in the
HDMEC (Figure 3F). Collectively, these results demonstrated
that the response of endothelial cells to anti-tumor drugs is
complex and species-specific.

Tumor xenografts with humanized vasculature grow
faster than xenografts with murine vasculature
To evaluate the impact of the species of endothelial cells on
tumor growth, we co-implanted a diverse group of human tumor
cells (UM-SSC-17B, HN12, or HeLa) with either HDMEC or
MDMEC in immunodefficient mice. Surprisingly, we observed
that in the three tumor cell models evaluated, the xenografts
vascularized with human endothelial cells grew faster than the
xenografts vascularized with mouse endothelial cells (Figure 2AE). However, we did not observe a significant difference in tumor
microvessel density when HDMEC and MDMEC tumors were
compared (Figure 2F-H). Therefore, the difference observed in
the rate of tumor growth is not simply due to having more blood
vessels in the tumors with humanized vasculature. Collectively,
these results imply that other factors besides simple access to blood
and oxygen are playing a role in the growth of xenograft tumors.

Figure 1. Human and mouse dermal microvascular endothelial cells have similar angiogenic potential in vitro and in vivo. (A-D)
Representative photomicrographs of human dermal microvascular endothelial cells (HDMEC) and mouse dermal microvascular endothelial cells
(MDMEC) stably transduced with GFP under light microscopy (A and B) and fluorescence microscopy (C and D). (E and F) Representative images of
capillary sprouts formed by HDMEC (E) and MDMEC (F) on 3-D type I collagen matrices. (G and H) Photomicrographs of representative fields of GFPimmunostaining (red color) used to localize the blood vessels formed by HDMEC (G) and MDMEC (G) 14 days after implantation in immunodefficient
mice. (I) The number of microvessels in implants populated with HDMEC or MDMEC. Microvessels were counted in 10 random microscopic fields/
scaffold (2006) in 6 scaffolds per group. Results are representative of 3 independent experiments, n = 6.
doi:10.1371/journal.pone.0084236.g001
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Figure 2. Tumor xenografts vascularized with human endothelial cells have similar microvessel density by grow faster than
xenografts vascularized with mouse endothelial cells. (A) Representative photographs of HeLa tumors vascularized with either HDMEC or
MDMEC. (B-D) Graphs depicting tumor growth of xenografts of HN12 (B), HeLa (C), UM-SCC-17B (D) vascularized with HDMEC or MDMEC. (E) Graph
depicting tumor volume at the end of the experimental period. Asterisk depicts p,0.05. (F and G) Representative photomicrographs of tumors
generated with UM-SCC-17B and HDMEC or MDMEC. Immunohistochemistry for GFP was performed to identify GFP-tagged endothelial cells. (H)
Microvessel density of xenograft tumors generated with UM-SCC-17B and HDMEC or MDMEC. Results are representative of 3 independent
experiments, n = 8.
doi:10.1371/journal.pone.0084236.g002

In attempt to explore possible mechanisms involved in the
differential responses observed in xenografts with humanized
vasculature, we interrogated the activity of the NF-kB pathway in
vivo. It is well known that the NF-kB pathway is widely used by
tumor cells as a regulator of genes that control cell proliferation
and survival, and has a significant impact in resistance to therapy.
Here, we observed higher levels of NF-kB activation (as measured
by nuclear translocation of p65) in xenografts vascularized with
human vessels (P,0.001), when compared to xenografts vascularized with mouse vessels (Figure 5A and B). Notably, this
pathway is particularly active around blood vessels in xenografts
with humanized vasculature (Figure 5C).

Human tumor xenografts with humanized vasculature
are more resistant to anti-cancer drugs than xenografts
with murine vasculature
Here, we co-transplanted human tumor cells with human or
murine endothelial cells bilaterally in immunodeficient mice.
When average tumor size reached 200 mm3, we began administration of either cisplatin or sunitinib. As expected, both cisplatin
and sunitinib inhibited tumor growth (Figure 4A-C). Immunohistochemical analysis revealed that both cisplatin and sunitinib
showed a more pronounced decrease in microvessel density when
tumors were vascularized with mouse blood vessels (Figure 4D).
These results correlate with the observation that the anti-cancer
effect of both drugs was more pronounced in tumors vascularized
with mouse vessels. Notably, if one compares tumor volume at the
end of the experimental period (30 days) with pre-treatment
volume, one concludes that sunitinib had a tumoristatic effect on
tumors vascularized with mouse endothelial cells, i.e. the average
growth of the of tumors was limited to approximately 1.2-fold
increase in volume during the experimental period (Figure 4B).
In contrast, sunitinib allowed for a 2.8-fold increase in the volume
of tumors vascularized with human vessels in the same mice
(Figure 4B). As expected, treated tumors are smaller than
untreated for both, xenografts vascularized with human or mouse
endothelial cells (Figure 4C). These experiments were repeated
with a second cell line (HeLa) and similar trends were observed
(data not shown).
Interestingly, the tumor growth inhibition in sunitinib-treated
groups was more apparent than in the cisplatin-treated groups
(Figure 4A and B). These results followed a different trend as
compared to the in vitro cytotoxicity results (Figure 3A and B).
This observation emphasizes the importance of combining
mechanistic in vitro studies with the testing in animal models.
Collectively, these data demonstrate that the response to anticancer therapy is significantly affected by the species of the
endothelial cells that vascularize the xenograft tumors.
PLOS ONE | www.plosone.org

Discussion
Several studies reported that the crosstalk between tumor cells
and endothelial cells plays an important role in tumor angiogenesis
and tumor growth. Wang and colleagues observed that the Notch
ligand Jagged1 from head and neck squamous cell carcinoma
(HNSCC) cells triggered Notch activation in neighboring endothelial cells and promoted capillary-like sprout formation [14].
Jagged1-expressing HNSCC cells significantly enhanced neovascularization and tumor growth in vivo. They concluded that the
direct interplay between tumor cells and endothelial cells promotes
tumor angiogenesis. We have reported that tumor cell-derived
VEGF induces Bcl-2 expression in endothelial cells [23], and that
the Bcl-2 expression levels in tumor endothelial cells correlate
directly with the rate of tumor growth [18–19]. Notably, Bcl-2 acts
as a signaling molecule by activating the NF-kB signaling pathway
and inducing expression of CXCL1 and CXCL8 [24] that in turn
enhance the invasive phenotype of neighboring tumor cells [21].
We also observed that endothelial cell-derived interleukin-6 (IL-6)
and epidermal growth factor (EGF) induce the activity of the signal
transducer and activator of transcription 3 (STAT3) and
extracellular signal-regulated kinase (ERK) in head and neck
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Figure 3. In vitro response of human and mouse endothelial cells to a chemotherapeutic and an anti-angiogenesis drug. (A and B)
The 48-hour cytotoxicity of cisplatin (A) and sunitinib (B) was evaluated by the SRB assay in HDMEC and MDMEC. Results are normalized against
vehicle control and initial plating density. (C and D) Fold-change difference in the percentage of apoptotic cells upon treatment with cisplatin (C) or
sunitinib (D) for 48 hours. Apoptosis was determined as the percentage of cells in Sub-G0/G1 by propidium iodide staining followed by flow
cytometry. (E and F) Effect of cisplatin (E) or sunitinib (F) on the cell cycle of HDMEC and MDMEC. Results are representative of 3 independent
experiments.
doi:10.1371/journal.pone.0084236.g003

cancer cells, resulting in enhanced tumor cell proliferation and
protection against anoikis [22]. We speculate that the results
reported here are mediated, at least in part, by the impact of
species on the effectiveness of the molecular crosstalk between
endothelial cells and tumor cells. An example of such differences
might be the prominent role that CXCL8 has in the crosstalk

PLOS ONE | www.plosone.org

between endothelial cells and tumor cells [22–24] and the wellknown absence of this protein in murine cells [25–26].
It is well known that chemokines (e.g. CXCL8) are potent
activators of NF-kB signaling [27]. NF-kB signaling plays a major
role in cancer progression and on response to therapy [28–29].
Here, we observed that xenografts vascularized with humanized
vessels express higher levels of nuclear p65 (indicative of active
5
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Figure 4. Human tumor xenografts vascularized with mouse endothelial cells is more responsive to a chemotherapeutic and an
anti-angiogenesis drug. Xenograft tumors were engineered in immunodefficient mice by the co-transplantation of human tumor cells and human
endothelial cells or human tumor cells and mouse endothelial cells seeded in biodegradable scaffolds measuring 66661 mm. (A) Graph depicting
the growth of human xenografts tumors (UM-SCC-17B cells) vascularized with HDMEC or MDMEC. As soon as we observed growth of the tumors
beyond the size of the scaffold (i.e. when average tumor volume was 180 mm3), mice began to receive either 4 mg/kg cisplatin (i.p.) every 5 days, or
40 mg/kg sunitinib (o.r.) daily. (B) Fold change difference between the pre-treatment volume of the tumors and the volume of the same tumors after
30 days of treatment with cisplatin or sunitinib. (C) Tumor volume at the end of treatment with cisplatin or sunitinib. (D) Graph depicting the number
of microvessels in tumor xenografts vascularized with HDMEC or MDMEC after treatment with cisplatin or sunitinib. Asterisk depicts P,0.05, as
compared with controls. Results are representative of 3 independent experiments, n = 8.
doi:10.1371/journal.pone.0084236.g004

and host endothelial cells (mouse vessels) do not migrate inside the
scaffold within the timeframe of these experiments, as demonstrated by our studies with endothelial cells stably transduced with
GFP. However, it is possible that soluble molecules secreted from
the endothelial cells from one scaffold can enter the circulation
and affect the behavior of the tumor generated in the other
scaffold. We speculate that any effect of circulating molecules
would minimize the potential impact of endothelial cell-species
considering that it would affect both tumors. Therefore, the
differences in tumor growth and response to therapy reported here
are despite and beyond any potential long-distance effect mediated
by endothelial cell-secreted molecules from different species
transplanted in the same mouse.
A well-known quote from Dr. Judah Folkman is ‘‘if you have
cancer and you are a mouse, we can take good care of you’’. This
statement reflects the observation that many drugs that are highly
effective in curing experimental cancer in mice, have shown
disappointing results in humans. In attempt to address this issue,
the use of patient-derived xenograft (PDX) models in mechanistic

NF-kB signaling), when compared to xenografts vascularized with
murine vessels. This difference in NF-kB activity is likely due to
species-specific factors that affect the crosstalk between endothelial
cells and tumor cells. Indeed, it is possible that the absence of
CXCL8 in murine endothelial cells might contribute to the lower
level of NF-kB activity in xenografts vascularized with murine
endothelial cells. We speculate that the high NF-kB activity
observed in xenografts with humanized vasculature might
contribute to the faster tumor growth and to the resistance to
therapy observed in these experimental tumors.
The approach used here involved the transplantation of a
scaffold containing tumor cells and human endothelial cells in one
side of the mouse, and transplantation of a scaffold containing the
same tumor cells but mouse endothelial cells in the other side. This
approach was designed to observe the potential impact of the
species of endothelial cells on tumor growth and response to
therapy with cisplatin and sunitinib, considering that the only
variable was mouse versus human endothelial cells. We observed
that human endothelial cells do not migrate outside the scaffolds

PLOS ONE | www.plosone.org
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Figure 5. Nuclear expression of p65 in human xenografts vascularized with human endothelial cells. Xenograft tumors were
engineered in immunodeficient mice by the co-transplantation of human tumor cells and human endothelial cells or human tumor
cells and mouse endothelial cells. (A) Immunofluorescence imaging of p65-FITC (green) counterstained with DAPI (blue), and then merged.
White arrowheads point to p65 expression in the nucleus in xenografts with humanized vasculature. Red arrowheads point to cytoplasmic p65 in
xenografts with murine vasculature. (B) Graph depicting the number of p65-positive cells in tumor xenografts vascularized with HDMEC or MDMEC
(n = 8) per high power field (4006). Asterisk depicts P,0.001. (C) Immunofluorescence imaging of p65-FITC (green) counterstained with DAPI (blue),
and then merged of a human blood vessel in a xenograft tumor.
doi:10.1371/journal.pone.0084236.g005

and developmental therapeutics studies has increased over the last
few years [30]. While PDX models demonstrate stability over a
few passages in mice, a certain drift of stromal components has
been observed with these models over time [30]. Also, we cannot
exclude the possibility of a decrease in the fraction of human blood
vessels using the scaffold model in long-term experiments. In
recognition of such potential limitation, we give preference to
short-term experiments (e.g. up to 2–3 months) with this model.
Considering the importance of the tumor microenvironment to
response to therapy, such drifts may hinder the translational
potential of these preclinical models. It is clear that all preclinical
tumor models have shortcomings, and that ideally one should use
a combination of complementary approaches to enhance the
predictive value of these methods for anti-cancer drug testing.
In conclusion, our studies demonstrated that xenograft human
tumors vascularized with murine vessels are highly responsive to
the anti-cancer drugs cisplatin and sunitinib. This might be due, at
least in part, to the fact that traditional xenografts do not
reproduce the effectiveness of the molecular crosstalk between
endothelial cells and tumor cells, thereby making them more
responsive to anti-cancer drugs. Collectively, this work supports
the concept that a model that brings together tumor and

endothelial cells of human origin offers a more rigorous approach
for mechanistic studies of the tumor microenvironment and for
translational studies involving the testing of anti-cancer drugs. It is
imperative though that this pilot study is followed by larger studies,
involving additional cell lines from several tumor types and
multiple anti-tumor drugs to determine more definitely the impact
of endothelial cell species on xenograft tumor growth and response
to therapy. Nevertheless, the pilot data presented here suggest a
potential explanation for the poor correlation frequently observed
between the results of preclinical testing of anti-cancer drugs in
traditional xenograft mouse models and the results of the clinical
trials with these drugs in patients with cancer.
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